[47] Metaxas Y,

Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, et al. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 2018;13(11):1784-1791. DOI: 10.1016/j. jtho.2018.08.007

[48] Goricar K, Kovac V, Dolzan V. The influence of PD-1 and PD-L1 polymorphisms on cisplatin-related toxicity in malignant mesothelioma (14th European ISSX Meeting). Accessed September 21, 2020. Available

**41**

cas.12267

*Current Mesothelioma Treatment and Future Perspectives*

with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy. 2010;18(4):843-851. DOI: 10.1038/

[56] Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, et al. CAR T-cell immunotherapy of MET-expressing

Oncoimmunology. 2017;6(12):e1363137. DOI: 10.1080/2162402X.2017.1363137

[57] Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunology Research. 2014;2(2):112-120. DOI: 10.1158/2326-6066.CIR-13-0170

malignant mesothelioma.

mt.2010.24

*DOI: http://dx.doi.org/10.5772/intechopen.94246*

at: http://issx.confex.com/issx/17euro/ webprogram/Paper37441.html.

[49] Tada Y, Takiguchi Y, Hiroshima K, Shimada H, Ueyama T, Nakamura M, et al. Gene therapy for malignant pleural mesothelioma: present and future. Oncology Research. 2008;17(6):239-246. DOI: 10.3727/096504008786991602

[50] Tagawa M, Tada Y, Shimada H, Hiroshima K. Gene therapy for malignant mesothelioma: current prospects and challenges. Cancer Gene Therapy. 2013;20(3):150-156. DOI:

[51] Suveg K, Putora PM, Berghmans T, Glatzer M, Kovac V, Cihoric N. Current

Albelda SM. Gene therapy for malignant pleural mesothelioma. Hematology/ Oncology Clinics of North America. 1998;12(3):553-568. DOI: 10.1016/

efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry. Lung Cancer. 2018;124:12-18. DOI: 10.1016/j.

[52] Sterman DH, Kaiser LR,

s0889-8588(05)70008-3

[53] Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T, et al. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer Science. 2013;104(11):1433-1439. DOI: 10.1111/

[54] Whilding LM, Maher J. CAR T-cell immunotherapy: The path from the by-road to the freeway? Molecular Oncology. 2015;9(10):1994-2018. DOI:

Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced

10.1016/j.molonc.2015.10.012

[55] Morgan RA, Yang JC,

10.1038/cgt.2013.1

lungcan.2018.07.007

*Current Mesothelioma Treatment and Future Perspectives DOI: http://dx.doi.org/10.5772/intechopen.94246*

at: http://issx.confex.com/issx/17euro/ webprogram/Paper37441.html.

*Mesothelioma*

[37] Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation:

polymerase genes influence treatment outcome in malignant mesothelioma. Pharmacogenomics. 2014;15(7):941-

950. DOI: 10.2217/pgs.14.14

10.1016/j.cllc.2014.06.009

[45] Zucali PA, Giovannetti E,

Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, et al. Thymidylate synthase and excision repair crosscomplementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/ carboplatin. Clinical Cancer

Research. 2011;17(8):2581-2590. DOI: 10.1158/1078-0432.CCR-10-2873

[46] Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. The Lancet Oncology. 2017;18(5):623-630. DOI: 10.1016/

Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, et al. Pembrolizumab

2018;13(11):1784-1791. DOI: 10.1016/j.

Accessed September 21, 2020. Available

[48] Goricar K, Kovac V, Dolzan V. The influence of PD-1 and PD-L1 polymorphisms on cisplatin-related toxicity in malignant mesothelioma (14th European ISSX Meeting).

as Palliative Immunotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology.

s1470-2045(17)30169-9

[47] Metaxas Y,

jtho.2018.08.007

[44] Powrozek T, Kowalski DM, Krawczyk P, Ramlau R, Kucharczyk T, Kalinka-Warzocha E, et al. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Clinical Lung Cancer. 2014;15(6):455-465. DOI:

current programs in five US medical centers. Annual Review of Pharmacology and Toxicology. 2015;55:89-106. DOI: 10.1146/ annurev-pharmtox-010814-124835

[38] Peterson JF, Roden DM,

s0140-6736(19)31278-4

[39] Ting S, Mairinger FD,

10.1016/j.cllc.2013.04.013

[40] Makridakis NM, Reichardt JK. Translesion DNA polymerases and cancer. Frontiers in Genetics. 2012;3:174.

Howell SB. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology. 2006;69(5):1748-1754. DOI: 10.1124/

[42] Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, et al. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drugresistant lung tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(48):20786-20791. DOI: 10.1073/pnas.1011409107

[43] Goricar K, Kovac V, Dolzan V. Polymorphisms in translesion

DOI: 10.3389/fgene.2012.00174

[41] Lin X, Okuda T, Trang J,

mol.105.020446

Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, et al. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinumbased chemotherapy in malignant pleural mesothelioma. Clinical Lung Cancer. 2013;14(5):558-567.e553. DOI:

Orlando LA, Ramirez AH, Mensah GA, Williams MS. Building evidence and measuring clinical outcomes for genomic medicine. Lancet.

2019;394(10198):604-610. DOI: 10.1016/

**40**

[49] Tada Y, Takiguchi Y, Hiroshima K, Shimada H, Ueyama T, Nakamura M, et al. Gene therapy for malignant pleural mesothelioma: present and future. Oncology Research. 2008;17(6):239-246. DOI: 10.3727/096504008786991602

[50] Tagawa M, Tada Y, Shimada H, Hiroshima K. Gene therapy for malignant mesothelioma: current prospects and challenges. Cancer Gene Therapy. 2013;20(3):150-156. DOI: 10.1038/cgt.2013.1

[51] Suveg K, Putora PM, Berghmans T, Glatzer M, Kovac V, Cihoric N. Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry. Lung Cancer. 2018;124:12-18. DOI: 10.1016/j. lungcan.2018.07.007

[52] Sterman DH, Kaiser LR, Albelda SM. Gene therapy for malignant pleural mesothelioma. Hematology/ Oncology Clinics of North America. 1998;12(3):553-568. DOI: 10.1016/ s0889-8588(05)70008-3

[53] Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T, et al. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer Science. 2013;104(11):1433-1439. DOI: 10.1111/ cas.12267

[54] Whilding LM, Maher J. CAR T-cell immunotherapy: The path from the by-road to the freeway? Molecular Oncology. 2015;9(10):1994-2018. DOI: 10.1016/j.molonc.2015.10.012

[55] Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced

with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy. 2010;18(4):843-851. DOI: 10.1038/ mt.2010.24

[56] Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, et al. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology. 2017;6(12):e1363137. DOI: 10.1080/2162402X.2017.1363137

[57] Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunology Research. 2014;2(2):112-120. DOI: 10.1158/2326-6066.CIR-13-0170

**43**

Section 3

Emerging Drugs
